BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33045196)

  • 1. The epigenetic treatment remodel genome-wide histone H4 hyper-acetylation patterns and affect signaling pathways in acute promyelocytic leukemia cells.
    Valiulienė G; Vitkevičienė A; Navakauskienė R
    Eur J Pharmacol; 2020 Dec; 889():173641. PubMed ID: 33045196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-leukemic effects of HDACi Belinostat and HMTi 3-Deazaneplanocin A on human acute promyelocytic leukemia cells.
    Valiulienė G; Stirblytė I; Jasnauskaitė M; Borutinskaitė V; Navakauskienė R
    Eur J Pharmacol; 2017 Mar; 799():143-153. PubMed ID: 28192098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Belinostat, a potent HDACi, exerts antileukaemic effect in human acute promyelocytic leukaemia cells via chromatin remodelling.
    Valiuliene G; Stirblyte I; Cicenaite D; Kaupinis A; Valius M; Navakauskiene R
    J Cell Mol Med; 2015 Jul; 19(7):1742-55. PubMed ID: 25864732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells.
    Savickiene J; Treigyte G; Valiuliene G; Stirblyte I; Navakauskiene R
    Anticancer Drugs; 2014 Sep; 25(8):938-49. PubMed ID: 24800886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone modifications patterns in tissues and tumours from acute promyelocytic leukemia xenograft model in response to combined epigenetic therapy.
    Valiulienė G; Treigytė G; Savickienė J; Matuzevičius D; Alksnė M; Jarašienė-Burinskaja R; Bukelskienė V; Navakauskas D; Navakauskienė R
    Biomed Pharmacother; 2016 Apr; 79():62-70. PubMed ID: 27044813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C/EBPα and PU.1 are involved in distinct differentiation responses of acute promyelocytic leukemia HL-60 and NB4 cells via chromatin remodeling.
    Savickiene J; Treigyte G; Vistartaite G; Tunaitis V; Magnusson KE; Navakauskiene R
    Differentiation; 2011 Jan; 81(1):57-67. PubMed ID: 20864248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential gene expression in retinoic acid-induced differentiation of acute promyelocytic leukemia cells, NB4 and HL-60 cells.
    Lee KH; Chang MY; Ahn JI; Yu DH; Jung SS; Choi JH; Noh YH; Lee YS; Ahn MJ
    Biochem Biophys Res Commun; 2002 Sep; 296(5):1125-33. PubMed ID: 12207890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibition promotes osteoblast maturation by altering the histone H4 epigenome and reduces Akt phosphorylation.
    Dudakovic A; Evans JM; Li Y; Middha S; McGee-Lawrence ME; van Wijnen AJ; Westendorf JJ
    J Biol Chem; 2013 Oct; 288(40):28783-91. PubMed ID: 23940046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoration of CCAAT enhancer binding protein α P42 induces myeloid differentiation and overcomes all-trans retinoic acid resistance in human acute promyelocytic leukemia NB4-R1 cells.
    Wang L; Xiao H; Zhang X; Liao W; Fu S; Huang H
    Int J Oncol; 2015 Nov; 47(5):1685-95. PubMed ID: 26397153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Green tea polyphenol EGCG causes anti-cancerous epigenetic modulations in acute promyelocytic leukemia cells.
    Borutinskaitė V; Virkšaitė A; Gudelytė G; Navakauskienė R
    Leuk Lymphoma; 2018 Feb; 59(2):469-478. PubMed ID: 28641467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Yang J; Koeffler HP; Yokoyama A
    Leukemia; 2008 Dec; 22(12):2159-68. PubMed ID: 18784743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antileukemic activity of combined epigenetic agents, DNMT inhibitors zebularine and RG108 with HDAC inhibitors, against promyelocytic leukemia HL-60 cells.
    Savickiene J; Treigyte G; Borutinskaite VV; Navakauskiene R
    Cell Mol Biol Lett; 2012 Dec; 17(4):501-25. PubMed ID: 22820861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic changes by zebularine leading to enhanced differentiation of human promyelocytic leukemia NB4 and KG1 cells.
    Savickiene J; Treigyte G; Jonusiene V; Bruzaite R; Borutinskaite VV; Navakauskiene R
    Mol Cell Biochem; 2012 Jan; 359(1-2):245-61. PubMed ID: 21842375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone Acetyltransferase p300/CREB-binding Protein-associated Factor (PCAF) Is Required for All-
    Sunami Y; Araki M; Kan S; Ito A; Hironaka Y; Imai M; Morishita S; Ohsaka A; Komatsu N
    J Biol Chem; 2017 Feb; 292(7):2815-2829. PubMed ID: 28053092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complex context relationships between DNA methylation and accessibility, histone marks, and hTERT gene expression in acute promyelocytic leukemia cells: perspectives for all-trans retinoic acid in cancer therapy.
    Garsuault D; Bouyer C; Nguyen E; Kandhari R; Prochazkova-Carlotti M; Chevret E; Forgez P; Ségal-Bendirdjian E
    Mol Oncol; 2020 Jun; 14(6):1310-1326. PubMed ID: 32239597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD / Shi-scid/scid mice.
    Kosugi H; Ito M; Yamamoto Y; Towatari M; Ito M; Ueda R; Saito H; Naoe T
    Jpn J Cancer Res; 2001 May; 92(5):529-36. PubMed ID: 11376562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.
    He LZ; Tolentino T; Grayson P; Zhong S; Warrell RP; Rifkind RA; Marks PA; Richon VM; Pandolfi PP
    J Clin Invest; 2001 Nov; 108(9):1321-30. PubMed ID: 11696577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment.
    Lin SF; Lin JD; Chou TC; Huang YY; Wong RJ
    PLoS One; 2013; 8(10):e77684. PubMed ID: 24155971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia.
    Martens JH; Brinkman AB; Simmer F; Francoijs KJ; Nebbioso A; Ferrara F; Altucci L; Stunnenberg HG
    Cancer Cell; 2010 Feb; 17(2):173-85. PubMed ID: 20159609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Euchromatic histone methyltransferase 2 inhibitor, BIX-01294, sensitizes human promyelocytic leukemia HL-60 and NB4 cells to growth inhibition and differentiation.
    Savickiene J; Treigyte G; Stirblyte I; Valiuliene G; Navakauskiene R
    Leuk Res; 2014 Jul; 38(7):822-9. PubMed ID: 24832370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.